Diabetes drug class appears to reduce recurrent gout flares

New data suggests that the glucose-lowering drug class sodium-glucose cotransporter-2 (SGLT2) inhibitors appear to reduce the risk for recurrent gout flares – and to lessen excess mortality – in people with gout and Type 2 diabetes.

These results are important because current management of gout is suboptimal, with many patients either not receiving adequate urate-lowering therapies (such as allopurinol) or stopping taking them – often because of initial (but preventable) gout flare.

However, trials among nearly 6000 adults with both Type 2 diabetes and gout from a United Kingdom primary care database fond that SGLT2 inhibitor treatment was associated with 19% fewer recurrent gout flares and 29% lower mortality.Moreover, unlike other urate-lowering therapies, there were no apparent increases in the risk of gout flares after initiating therapy

In addition to lowering glucose, SGLT2 inhibitors also reduce the risk for major adverse cardiovascular events and all-cause mortality in people, regardless of their diabetes status.

To read more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags